Drugs / LAFUVITUG
LAFUVITUG
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03468582 | Feb 2018 → Jan 2020 | HIV infectious disease | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT03588715 | Jun 2020 → Dec 2021 | AIDS | Luis Montaner | Unknown | No outcome recorded |
| Phase 1 | NCT03063788 | Sep 2018 → Feb 2020 | HIV infectious disease | Bayside Health | Completed | No outcome recorded |
| Phase 1 | NCT03571204 | Sep 2018 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT03526848 | Jun 2018 → Sep 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02824536 | Jun 2016 → Jan 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02825797 | Jun 2016 → Aug 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT02018510 | Jan 2014 → Jan 2016 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04560569 | Nov 2021 → Nov 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | Met primary |
| Phase 2 | NCT04819347 | May 2021 → Jun 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04720742 | Feb 2021 → Mar 2022 | HIV infectious disease | IrsiCaixa | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03719664 | Dec 2018 → Dec 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02850016 | Jan 2017 → Dec 2020 | HIV infectious disease | Rockefeller University | Completed | Missed primary |
| Phase 2 | NCT02588586 | Oct 2015 → Feb 2018 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 2 | NCT02446847 | Mar 2015 → Mar 2017 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03837756 Comparator | May 2019 → Jul 2022 | HIV infectious disease | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT03041012 Comparator | Jan 2017 → Aug 2021 | HIV infectious disease | Aarhus University Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-02-21 | Gilead Sciences | Results Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies gilead.com ↗
Results from the Phase 2a TITAN trial show that dual treatment with the broadly neutralizing HIV antibodies (bNAbs; 3BNC117 and 10-1074) led to a significant delay in viral rebound. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-02-21 | Gilead Sciences | Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies gilead.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAFUVITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315006 ↗ |
| Known as | 3BNC117 | “During the first 8 months, the participants will be infused once per month with a combination of the broadly neutralizing antibodies (bNAbs) 3BNC117 and 10-1074” NCT04720742 ↗ |
| Known as | Monoclonal Antibody 3BNC117 | “Monoclonal Antibody 3BNC117” NCT02824536 ↗ |
| Action | Inhibit | “suppress viral replication in subjects who are not taking ART” NCT03571204 ↗ |
| Modality | Monoclonal antibody | “A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers” NCT02018510 ↗ |
| Route | Intravenous | “IV administration” NCT02018510 ↗ |